Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Shares in Denmark's pharmaceutical giant Novo Nordisk (NYSE: NVO) were lower by 4% as of 11 a.m. ET today. The move comes as ...

The NNF – a philanthropic non-profit organisation that owns a controlling stake in Danish drugmaker Novo Nordisk – has been ...

Raise awareness of obesity as a chronic, multifactorial disease. Reduce stigma and myths that hinder early care. Encourage ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See why NVO stock is a buy.

Novo Nordisk has been actively pursuing licensing deals over the past six months. There are other good reasons to consider investing in Novo Nordisk right now. It wasn't so long ago that Novo Nordisk ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...

Novo Nordisk launches Wegovy, its anti-obesity drug, in India. Targeting a large obese population, Wegovy aims to improve ...

It wasn't so long ago that Novo Nordisk(NYSE: NVO), a Denmark-based pharmaceutical company, seemed to be firing on all cylinders. However, the past year has been challenging for the drugmaker.

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an ...